Shares of Lantheus Holdings (NASDAQ: LNTH) soared 5.15% in pre-market trading on Wednesday, following the company's strong fourth-quarter 2024 financial results and upbeat outlook for the year ahead.
The radiopharmaceutical company reported a 10.5% year-over-year increase in revenue to $391.1 million for the fourth quarter, exceeding analysts' expectations of $377.1 million. Adjusted earnings per share (EPS) came in at $1.59, surpassing the consensus estimate of $1.54.
Lantheus' blockbuster radiodiagnostic product, PYLARIFY, continued to drive growth, with sales reaching $1.06 billion for the full year 2024, marking a significant milestone as the first radiodiagnostic to achieve blockbuster status.
For the full year 2025, the company provided revenue guidance in the range of $1.545 billion to $1.61 billion, slightly below analysts' expectations of $1.605 billion. However, Lantheus' adjusted EPS guidance of $7.00 to $7.20 exceeded the consensus estimate of $6.95.
Lantheus also highlighted its strategic initiatives to enhance its radiopharmaceutical leadership, including the acquisition of Life Molecular Imaging Ltd. and Evergreen Theragnostics Inc. These acquisitions are expected to diversify the company's portfolio and expand its pipeline with late-stage and early-stage assets.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.